Quanterix Co-Inventor of Simoa® David Walt Receives Kabiller Prize in Nanoscience and Nanomedicine

Northwestern University’s prestigious biennial award honors those who have made a lasting impact in the field of nanotechnology

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, has announced that David Walt, co-inventor of Simoa®, was awarded the Kabiller Prize in Nanoscience and Nanomedicine by Northwestern University. Established in 2015 by entrepreneur and Northwestern alumnus David G. Kabiller, the Kabiller Prize is awarded biennially for a career in outstanding achievement in the field of nanotechnology and its application to medicine and biology. It is one of three awards recognizing top scholars, including one pioneer, one young investigator and one rising star in the field.

“The Quanterix team sends our heartfelt congratulations to David on receiving the prestigious Kabiller Prize in Nanoscience and Nanomedicine,” said Kevin Hrusovsky, Chairman and CEO, Quanterix Corporation. “As an integral part of Quanterix’ innovative, ultrasensitive biomarker detection platform, Simoa®, we’re honored to see firsthand the far-reaching and meaningful impact of David’s work. He is a true pioneer of modern medicine and a champion of the precision health movement. We look forward to seeing how his commitment to technology innovations will continue to advance medicine.”

Walt, the Hansjörg Wyss Professor of Biologically Inspired Engineering at Harvard Medical School and professor of pathology at Brigham and Women’s Hospital, was recognized for his transformative work in the development of ultrasensitive single-molecule array detection technology, which is revolutionizing the way cancer, infectious disease and neurological disorders are diagnosed and treated. Walt also played an integral role in the development of Quanterix’ core digital immunoassay platform, Simoa®, and the creation of Illumina, Inc.’s microwell-based DNA array.

Award recipients are reviewed and chosen by a selection committee made up of renowned, independent global experts in nanotechnology and its applications in the fields of medicine and biology.

Quanterix’ digital health solution, Simoa®, is changing the way researchers detect and treat disease by granting them the tools to closely examine critical biomarkers in extremely low concentrations of blood. The first-of-its-kind detection capabilities are currently being used for applications in major therapeutic areas, including neurology, oncology, cardiology, inflammation and infectious disease. Since its initial development, Quanterix has continued to innovate and scale Simoa® to become one of the most sensitive disease detection platforms on the market across new instruments, such as its HD-X Analyzer™ and through the company’s Accelerator Laboratory Services. More than 1,400 peer-reviewed scientific research publications have leveraged the technology to power precision health breakthroughs.

To learn more about Quanterix’ Simoa® technology, visit: https://www.quanterix.com/simoa-technology/.

About Quanterix

Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit https://www.quanterix.com/.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.